Drugs / Salirasib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00531401 | Sep 2007 → Nov 2009 | non-small cell lung carcinoma | Concordia Pharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Salirasib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00531401 ↗ |